Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FORUM MARKETS IncATNF · Entity 7020 | Director | September 04, 2023 | September 08, 2023 |
| MERRIMACK PHARMACEUTICALS INCMACK · Entity 95770 | Director | December 31, 2021 | January 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FORUM MARKETS Inc
Report date September 04, 2023 · Filed September 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,409 |
Reported balance
After 2023-09-04 transaction · row 1
1 source rowRow 1 · 2023-09-04 · Grant · Acquired 21,455 · Balance 24,409 F1: Issued in consideration for serving on the Board of Directors and as a Member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board of Directors, for the quarter ended June 30, 2023. Granted under the registrant's Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2033-09-04 | Direct | 15,000 |
Reported balance
After 2023-09-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-04 · Grant · Acquired 15,000 · Balance 15,000 F2: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F3: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Issued in consideration for serving on the Board of Directors and as a Member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board of Directors, for the quarter ended June 30, 2023. Granted under the registrant's Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
F2: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
F3: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates.
MERRIMACK PHARMACEUTICALS INC
Report date December 31, 2021 · Filed January 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-12-31 transaction · row 1
1 source rowRow 1 · 2021-12-31 · Sale · Disposed 1,000 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2023 Filed Sep 8, 2023 20:00 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001213900-23-075377 · ownership.xml · derivative · entry 2 RAY RUSSELL T · CIK 0001225960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-09-04 F2 · kind: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F2 · price: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F3 · derivative.exercise_date: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates. Read SEC document |
| September 04, 2023 Filed Sep 8, 2023 20:00 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantCommon Stock | 21,455 | $1.36 | $29,178.80 |
DisclosureSEC source: 0001213900-23-075377 · ownership.xml · nonDerivative · entry 1 RAY RUSSELL T · CIK 0001225960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,409 F1 · kind: Issued in consideration for serving on the Board of Directors and as a Member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board of Directors, for the quarter ended June 30, 2023. Granted under the registrant's Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F1 · price: Issued in consideration for serving on the Board of Directors and as a Member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board of Directors, for the quarter ended June 30, 2023. Granted under the registrant's Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 21:01 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantCommon Stock | 30,702 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-068720 · ownership.xml · nonDerivative · entry 1 RAY RUSSELL T · CIK 0001225960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,068 F1 · kind: Issued in consideration for serving on the Board of Directors and as a Member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board of Directors, for the quarter ended September 30, 2022. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F1 · price: Issued in consideration for serving on the Board of Directors and as a Member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board of Directors, for the quarter ended September 30, 2022. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 20:17 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantCommon Stock | 13,068 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-042959 · ownership.xml · nonDerivative · entry 1 RAY RUSSELL T · CIK 0001225960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,366 F1 · kind: Issued in consideration for serving on the Board of Directors and as a Member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board of Directors, for the quarter ended June 30, 2022. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F1 · price: Issued in consideration for serving on the Board of Directors and as a Member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board of Directors, for the quarter ended June 30, 2022. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:34 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001213900-22-028982 · ownership.xml · derivative · entry 2 RAY RUSSELL T · CIK 0001225960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2032-05-19 F2 · kind: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F2 · price: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F3 · derivative.exercise_date: The Options vest at the rate of 1/39th of such options ratably on a monthly basis over the following 39 months following the grant date, on the last day of each calendar month (beginning on May 31, 2022), subject to the holder's continued service to the Company. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:34 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantCommon Stock | 10,570 | $1.36 | $14,375.20 |
DisclosureSEC source: 0001213900-22-028982 · ownership.xml · nonDerivative · entry 1 RAY RUSSELL T · CIK 0001225960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,570 F1 · kind: Issued in consideration for serving on the Board of Directors and as a Member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board of Directors, for the quarter ended March 31, 2022. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F1 · price: Issued in consideration for serving on the Board of Directors and as a Member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board of Directors, for the quarter ended March 31, 2022. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. Read SEC document |
| May 19, 2022 Filed Jul 29, 2022 20:16 UTC Amendment | FORUM MARKETS Inc ATNF · Entity 7020 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001213900-22-042957 · ownership.xml · derivative · entry 2 RAY RUSSELL T · CIK 0001225960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2032-05-19 F2 · kind: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F2 · price: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F3 · derivative.exercise_date: The Options vest at the rate of 1/39th of such options ratably on a monthly basis over the following 39 months following the grant date, on the last day of each calendar month (beginning on May 31, 2022), subject to the holder's continued service to the Company. Read SEC document |
| May 19, 2022 Filed Jul 29, 2022 20:16 UTC Amendment | FORUM MARKETS Inc ATNF · Entity 7020 | GrantCommon Stock | 10,570 | $1.36 | $14,375.20 |
DisclosureSEC source: 0001213900-22-042957 · ownership.xml · nonDerivative · entry 1 RAY RUSSELL T · CIK 0001225960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,298 F1 · kind: Issued in consideration for serving on the Board of Directors and as a Member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board of Directors, for the quarter ended March 31, 2022. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F1 · price: Issued in consideration for serving on the Board of Directors and as a Member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board of Directors, for the quarter ended March 31, 2022. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 21:33 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantCommon Stock | 4,728 | $3.04 | $14,373.12 |
DisclosureSEC source: 0001213900-22-002425 · ownership.xml · nonDerivative · entry 1 RAY RUSSELL T · CIK 0001225960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,728 F1 · kind: Issued in consideration for serving on the Board of Directors and as a Member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board of Directors, for the quarter ended December 31, 2021. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) pursuant to Rule 16b-3. F1 · price: Issued in consideration for serving on the Board of Directors and as a Member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board of Directors, for the quarter ended December 31, 2021. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) pursuant to Rule 16b-3. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 16:05 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | SaleCommon Stock | 1,000 | $3.84 | $3,839.80 |
DisclosureSEC source: 0000899243-22-000473 · doc4.xml · nonDerivative · entry 1 RAY RUSSELL T · CIK 0001225960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 20:18 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 79,000 | $0.00 Strike: $7.56 | $0.00 |
DisclosureSEC source: 0001213900-21-040519 · ownership.xml · derivative · entry 2 RAY RUSSELL T · CIK 0001225960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,000 Underlying: Common Stock · 79,000 shares Expires 2031-08-04 F1 · kind: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) of the Securities Exchange Act of 1934 pursuant to Rule 16b-3 promulgated under the Exchange Act. F1 · price: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) of the Securities Exchange Act of 1934 pursuant to Rule 16b-3 promulgated under the Exchange Act. F2 · derivative.exercise_date: The Options vest at the rate of 1/48th of such options ratably on a monthly basis over the following 48 months following the grant date, on the last day of each calendar month (beginning on August 31, 2021), subject to the holder's continued service to the Company. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 16:05 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | GrantStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0000899243-21-023538 · doc4.xml · derivative · entry 1 RAY RUSSELL T · CIK 0001225960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: This option vests as to 1/4th of the total number of shares on 7/1/21 and an additional 1/4th of the total number of shares at the end of each successive three month period thereafter until 4/1/22. Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 21:09 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | GrantStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-20-021047 · doc4.xml · derivative · entry 1 RAY RUSSELL T · CIK 0001225960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2030-07-29 F1 · derivative.exercise_date: This option vests as to 1/4th of the total number of shares on 10/30/20 and an additional 1/4th of the total number of shares at the end of each successive three month period thereafter until 7/30/21, provided that such option shall vest in full on the date that is one business day prior to the date of the issuer's next annual meeting of stockholders (if earlier than 7/30/21). Read SEC document |
| October 17, 2019 Filed Oct 21, 2019 07:58 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | GrantStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0000899243-19-025791 · doc4.xml · derivative · entry 1 RAY RUSSELL T · CIK 0001225960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2029-10-16 F1 · derivative.exercise_date: This option vests as to 1/4th of the total number of shares on 1/17/20 and an additional 1/4th of the total number of shares at the end of each successive three month period thereafter until 10/17/20, provided that such option shall vest in full on the date that is one business day prior to the date of the issuer's next annual meeting of stockholders (if earlier than 10/17/20). Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:34 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | GrantStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $9.67 | $0.00 |
DisclosureSEC source: 0001209191-18-038082 · doc4.xml · derivative · entry 1 RAY RUSSELL T · CIK 0001225960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2028-06-12 F1 · derivative.exercise_date: This option vests as to 1/4th of the total number of shares on 9/13/18 and an additional 1/4th of the total number of shares at the end of each successive three month period thereafter until 6/13/19, provided that such option shall vest in full on the date that is one business day prior to the date of the issuer's next annual meeting of stockholders (if earlier than 6/13/19). Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 16:49 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $13.99 | $0.00 |
DisclosureSEC source: 0001209191-17-053007 · doc4.xml · derivative · entry 1 RAY RUSSELL T · CIK 0001225960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-09-12 F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.